Full TitlePhase I/II Study of Canakinumab with Chemoradiation and Durvalumab for Unresected Locally-Advanced Non-Small Cell Lung Cancer (CHORUS)
The combination of chemotherapy, radiation therapy, and durvalumab is a usual treatment for non-small cell lung cancer (NSCLC). Researchers want to know if adding canakinumab to this standard combination may improve the effectiveness of treatment.
The purpose of this study to find out whether canakinumab given in combination with chemoradiation and durvalumab is an effective and safe treatment for people with inoperable stage III NSCLC. Canakinumab is given as a subcutaneous (under the skin) injection and intravenously (by vein), and the other medications are given intravenously.
Who Can Join
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have stage IIIA-C NSCLC.
- Patients must be candidates for chemoradiation and durvalumab.
- Patients must be physically well enough that they are fully ambulatory, capable of all self-care, and capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Narek Shaverdian at 631-212-6323.